Find information on thousands of medical conditions and prescription drugs.

Charcot disease

Amyotrophic lateral sclerosis (ALS, sometimes called Lou Gehrig's disease) is a progressive, invariably fatal motor neurone disease. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, waste away (atrophy), and twitch (fasciculations). Eventually, the ability of the brain to start and control voluntary movement is lost. more...

Home
Diseases
A
B
C
Angioedema
C syndrome
Cacophobia
Café au lait spot
Calcinosis cutis
Calculi
Campylobacter
Canavan leukodystrophy
Cancer
Candidiasis
Canga's bead symptom
Canine distemper
Carcinoid syndrome
Carcinoma, squamous cell
Carcinophobia
Cardiac arrest
Cardiofaciocutaneous...
Cardiomyopathy
Cardiophobia
Cardiospasm
Carnitine transporter...
Carnitine-acylcarnitine...
Caroli disease
Carotenemia
Carpal tunnel syndrome
Carpenter syndrome
Cartilage-hair hypoplasia
Castleman's disease
Cat-scratch disease
CATCH 22 syndrome
Causalgia
Cayler syndrome
CCHS
CDG syndrome
CDG syndrome type 1A
Celiac sprue
Cenani Lenz syndactylism
Ceramidase deficiency
Cerebellar ataxia
Cerebellar hypoplasia
Cerebral amyloid angiopathy
Cerebral aneurysm
Cerebral cavernous...
Cerebral gigantism
Cerebral palsy
Cerebral thrombosis
Ceroid lipofuscinois,...
Cervical cancer
Chagas disease
Chalazion
Chancroid
Charcot disease
Charcot-Marie-Tooth disease
CHARGE Association
Chediak-Higashi syndrome
Chemodectoma
Cherubism
Chickenpox
Chikungunya
Childhood disintegrative...
Chionophobia
Chlamydia
Chlamydia trachomatis
Cholangiocarcinoma
Cholecystitis
Cholelithiasis
Cholera
Cholestasis
Cholesterol pneumonia
Chondrocalcinosis
Chondrodystrophy
Chondromalacia
Chondrosarcoma
Chorea (disease)
Chorea acanthocytosis
Choriocarcinoma
Chorioretinitis
Choroid plexus cyst
Christmas disease
Chromhidrosis
Chromophobia
Chromosome 15q, partial...
Chromosome 15q, trisomy
Chromosome 22,...
Chronic fatigue immune...
Chronic fatigue syndrome
Chronic granulomatous...
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Chronic obstructive...
Chronic renal failure
Churg-Strauss syndrome
Ciguatera fish poisoning
Cinchonism
Citrullinemia
Cleft lip
Cleft palate
Climacophobia
Clinophobia
Cloacal exstrophy
Clubfoot
Cluster headache
Coccidioidomycosis
Cockayne's syndrome
Coffin-Lowry syndrome
Colitis
Color blindness
Colorado tick fever
Combined hyperlipidemia,...
Common cold
Common variable...
Compartment syndrome
Conductive hearing loss
Condyloma
Condyloma acuminatum
Cone dystrophy
Congenital adrenal...
Congenital afibrinogenemia
Congenital diaphragmatic...
Congenital erythropoietic...
Congenital facial diplegia
Congenital hypothyroidism
Congenital ichthyosis
Congenital syphilis
Congenital toxoplasmosis
Congestive heart disease
Conjunctivitis
Conn's syndrome
Constitutional growth delay
Conversion disorder
Coprophobia
Coproporhyria
Cor pulmonale
Cor triatriatum
Cornelia de Lange syndrome
Coronary heart disease
Cortical dysplasia
Corticobasal degeneration
Costello syndrome
Costochondritis
Cowpox
Craniodiaphyseal dysplasia
Craniofacial dysostosis
Craniostenosis
Craniosynostosis
CREST syndrome
Cretinism
Creutzfeldt-Jakob disease
Cri du chat
Cri du chat
Crohn's disease
Croup
Crouzon syndrome
Crouzonodermoskeletal...
Crow-Fukase syndrome
Cryoglobulinemia
Cryophobia
Cryptococcosis
Crystallophobia
Cushing's syndrome
Cutaneous larva migrans
Cutis verticis gyrata
Cyclic neutropenia
Cyclic vomiting syndrome
Cystic fibrosis
Cystinosis
Cystinuria
Cytomegalovirus
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

ALS causes weakness with a wide range of disabilities. Eventually, all muscles under voluntary control are affected, and patients lose their strength and the ability to move their arms, legs, and body. When muscles in the diaphragm and chest wall fail, patients lose the ability to breathe without help from mechanical ventilation. Most people with ALS die from respiratory failure, usually within 3 to 5 years from the onset of symptoms. However, about 10 % of ALS patients survive for 10 or more years.

Epidemiology

As many as 20,000 Americans have ALS, and an estimated 5,000 people in the United States are diagnosed with the disease each year. ALS is one of the most common neuromuscular diseases worldwide, and people of all races and ethnic backgrounds are affected. ALS most commonly strikes people between 40 and 60 years of age, but younger and older people also can develop the disease. Men are affected more often than women.

In 90 to 95 % of all ALS cases, the disease occurs apparently at random with no clearly associated risk factors. Patients do not have a family history of the disease, and their family members are not considered to be at increased risk for developing ALS.

About 5 to 10 % of all ALS cases are inherited. The familial form of ALS usually results from a pattern of inheritance that requires only one parent to carry the gene responsible for the disease. About 20 % of all familial cases result from a specific genetic defect that leads to mutation of the enzyme known as superoxide dismutase 1 (SOD1). Research on this mutation is providing clues about the possible causes of motor neuron death in ALS. Not all familial ALS cases are due to the SOD1 mutation, therefore other unidentified genetic causes clearly exist.

Symptoms

The onset of ALS may be so subtle that the symptoms are frequently overlooked. The earliest symptoms may include twitching, cramping, or stiffness of muscles; muscle weakness affecting an arm or a leg; slurred and nasal speech; or difficulty chewing or swallowing. These general complaints then develop into more obvious weakness or atrophy that may cause a physician to suspect ALS.

The parts of the body affected by early symptoms of ALS depend on which muscles in the body are damaged first. In some cases, symptoms initially affect one of the legs, and patients experience awkwardness when walking or running or they notice that they are tripping or stumbling more often. Some patients first see the effects of the disease on a hand or arm as they experience difficulty with simple tasks requiring manual dexterity such as buttoning a shirt, writing, or turning a key in a lock. Other patients notice speech problems.

Read more at Wikipedia.org


[List your site here Free!]


Problems with the nomenclature of Charcot's osteoarthropathy
From Diabetic Foot, The, 9/22/05 by Ali Foster

Introduction

Charcot's osteoarthropathy is a complication of diabetic neuropathy and some other neurological conditions. Scientific nomenclature should be accurate and specific. However, when describing Charcot's osteoarthropathy up until now, names have been chosen with lack of precision, extraordinary pedantry and frank inaccuracy. If there is confusion over the name of the condition, there is a consequent risk of confusion over diagnosis and treatment, which may be reflected in the alarming morbidity associated with this condition. Here, the author argues that if the term Charcot's osteoarthropathy could be generally adopted, it would put an end to decades of confusion.

KEY WORDS

* Charcot's osteoarthropathy

* Confused nomenclature

* Accurate classification

* Universal terminology

**********

There is no consensus on the correct name for Charcot's osteoarthropathy, which can lead to imprecise diagnosis and management. This can adversely affect outcomes in patients with diabetic foot problems.

Early descriptions of Charcot's osteoarthropathy

Charcot's osteoarthropathy is a complication of diabetic neuropathy and some other neurological conditions (Table 1).

William Musgrave, writing in Antiquitates Britanno-Belgicae (1748), described cases of neuropathic arthritis and emphasised the need to recognise that arthritis could be secondary to other diseases (Kelly, 1963). In 1831, JK Mitchell of Philadelphia wrote about 12 cases of joint afflictions (arthritis) in patients with lesions of the spinal cord (Mitchell, 1831).

The eminent 19th Century neurophysiologist Professor Jean-Martin Charcot (1868a; 1868b) described a progressive, destructive arthropathy in a group of his patients with neurosyphilis (tabes dorsalis) at La Salpetriere Hospital in Paris, but Charcot himself acknowledged that Mitchell's was the earlier report. However, in 1882, the Rapport du Congres, published in London, first named these distinct pathological changes as 'Charcot's joint' (MacCormac and Klockmann, 1881):

Charcot had a remarkable and admirable ability to see what was new and what was logically linked, and his name is associated with many other medical conditions (Table 2). In 1936, William Reilly Jordan made the first report of Charcot's osteoarthropathy in a patient with diabetes (Jordan, 1936).

Confused nomenclature and lack of consensus

Although over 200 papers and numerous book chapters have been devoted to Charcot's osteoarthropathy--and in spite of the different stages of the condition having been described in considerable detail by Harris and Brand (1966), Lennox (1974), Horibe et al (1988), Sanders and Frykberg (1991), Barjon (1993), Brodsky and Rouse (1993), Johnson (1995) and Dounis (1997)--there is no consensus as to what is the most appropriate or correct name (Table 3). In a review of Charcot's osteoarthropathy by Solomon Tesfaye's group (Rajbhandari et al, 2002), 39 names were used to describe Charcot's osteoarthropathy in the references cited (Table 4).

Furthermore, many authors have allocated different names to Charcot's osteoarthropathy in articles authored or co-authored by them over a period of time. There is no consensus and much confusion.

Discussion

For practical purposes, clinicians managing Charcot's osteoarthropathy need to know:

* the name of the disease

* the stage (acute, bony destruction, resolving or resolved)

* the site affected (in patients with diabetes this will usually be forefoot, midfoot, hindfoot, ankle or, rarely, the knee)

* the type and degree of residual deformity (rocker bottom, medial convexity) after the acute stage has resolved

* the presence of ulceration, infection or instability of a joint.

The name of the condition alone is not enough to guide treatment and predict outcomes.

However, Newman (1987) wrote of Charcot's osteoarthropathy:

There is no consensus on the most appropriate name for Charcot's osteoarthropathy. The International Consensus on the Diabetic Foot (International Working Group on the Diabetic Foot, 1999) suggested the rather unwieldy name of 'neuro-osteoarthropathy (Charcot-foot)', but this name has not been adopted.

It is always desirable to use language to order concepts in a way that is logically sound, elegant and well suited for potential users of the description. Some names are steeped in history: 'diabetes mellitus', the 'honey siphon' of the ancient Greeks, for instance, describes some of the symptoms of untreated diabetes very well, so there is a good reason for preserving it.

Scientific nomenclature should be accurate and specific. Up until now, however, when describing Charcot's osteoarthropathy, names have been chosen with a lack of precision, extraordinary pedantry and frank inaccuracy. In some cases, the desire to cover all possible eventualities has resulted in a 'scattergun' approach, with every possible descriptive term appended together with afterthoughts in brackets.

Few would deny that Professor Jean-Martin Charcot was both deserving of honour and possessed of a beguiling name, as reflected by the fact that there are at least 14 medical eponyms associated with this great physician.

If the first describer of a disease is the one to be honoured, the disease should be called 'Musgrave's' or 'Mitchell's' osteoarthropathy. If we want a specific name for Charcot's osteoarthropathy in diabetes, the disease should be 'Jordan's' osteoarthropathy. However, once a name has become firmly associated with a condition it is hard to change it, so it seems that potential claimants such as Musgrave, Mitchell and Jordan had better bow down to Charcot.

Regarding precise semantics, Charcot's osteoarthropathy is not just an arthropathy; it can also affect bone alone, so it is properly described as an osteoarthropathy. In the early stages it may be hard to tell whether an initial osteopathy will progress to an arthropathy. Some radiologists, therefore, describe it as an osteopathy. However, since it is usually more than just osteopathy, affecting joints as well as bones, arthropathy should be included in the name.

Although Charcot described many other diseases and syndromes (Table 2), he did not describe any other bone and joint condition, so there is no possibility of confusion when we refer to Charcot's osteoarthropathy. However, we should not just call Charcot's osteoarthropathy 'the Charcot foot'.

Conclusion

Imprecise description is unacceptable in diagnosis or treatment, and it should not be acceptable in the nomenclature of Charcot's osteoarthropathy. Many clinicians may be reading or writing about Charcot's osteoarthropathy in a language that is not their own first language. If there is confusion over the name of the condition, there is a consequent risk of confusion over diagnosis and treatment, which may be reflected in the alarming morbidity associated with this condition (Jeffcoate, 2005).

The author has no doubt that Charcot's osteoarthropathy is the most appropriate name, and justly honours a great neurophysiologist and acute observer. If this nomenclature could be generally adopted, it would put an end to decades of confusion.

Barjon MC (1993) Les osteoarthropathies destructices due pied diabetique. In: Herisson C, Simon L (eds) Le Pied Diabetique. Masson, Paris: 77-91

Brodsky JW, Rouse AM (1993) Exostectomy for symptomatic bony prominences in diabetic Charcot foot. Clinical Orthopaedics 296: 21-6

Charcot JM (1868a) Sur quelques arthropathies qui paraissent dependre d'une lesion du cerveau ou de la moelle epiniere. Archives of Physiology and Normal Pathology 1: 161-78

Charcot JM (1868b) On some arthropathies apparently related to a lesion of the brain or spinal cord. Translated and edited by Hoche G, Sanders LJ (1992). Journal of the History of Neuroscience 1: 75-87

Dounis E (1997) Charcot neuropathic osteoarthropathy of the foot. Acta Orthopaedica Hellenica 48: 281-95

Harris JR, Brand PW (1966) Patterns of disintegration of the tarsus in the anesthetic foot. Journal of Bone and Joint Surgery 5: 95-7

Horibe S, Tada K, Magano J (1988) Neuroarthropathy of the foot in leprosy. Journal of Bone and Joint Surgery 70B(3): 481-85

International Working Group on the Diabetic Foot (1999) International Consensus on the Diabetic Foot. International Diabetes Federation, Brussels

Jeffcoate W (2005) Charcot foot--why still so difficult to treat? Diabetic Foot Conference, Edinburgh

Johnson JE (1995) Neuropathic (Charcot) arthropathy of the foot and ankle. American Academy of Orthopedic Surgeons Instructional course. No. 349

Jordan WR (1936) Neuritic manifestations in diabetes mellitus. Archives of Internal Medicine 57: 307-66

Kelly M (1963) De arthritide symptomatica of William Musgrave (1657-1721): his description of neuropathic arthritis. Bulletin of the History of Medicine 37: 372-7

Lennox WM (1974) Surgical treatment of chronic deformities of the anaesthetic foot. In: F McDowell, CP Enna, eds. Surgical rehabilitation in leprosy, and in peripheral nerve disorders. Williams and Wilkins, Baltimore, MD, 350-372

MacCormac W, Klockmann JW (1881) Transactions of the international medical congress. Ballantyne, Hanson & Co., London

Mitchell JK (1831) On a new practice in acute and chronic rheumatism. American Journal of Medical Science 8: 55

Newman JH (1987) Non-infective disease of the diabetic foot. In: AJM Boulton, H Connor, JD Ward, eds. The Foot in Diabetes. John Wiley & Sons, Chichester

Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S (2002) Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45: 1085-96

Sanders LJ, Frykberg RG (1991) Diabetic neuropathic osteoarthropathy: the Charcot foot. In: Frykberg RG (ed) The High Risk Foot in Diabetes Mellitus. Churchill Livingstone, New York, 297-338

If you have any comments on this article, please write to The Diabetic Foot journal.

SB Communications Group, 15 Mandeville Courtyard, 142 Battersea Park Road, London SW11 4NB

Email: editorial@sbcommunicationsgroup.com

Fax: 020 7627 1570

RELATED ARTICLE: ARTICLE POINTS

1 There is no consensus on the most appropriate name for Charcot's osteoarthropathy.

2 Charcot's osteoarthropathy is a complication of diabetic neuropathy and some other neurological conditions.

3 Imprecise description is unacceptable in diagnosis or treatment, and it should not be acceptable in the nomenclature of the Charcot foot.

4 If the term 'Charcot's osteoarthropathy' could be generally adopted, it would put an end to decades of confusion.

RELATED ARTICLE: PAGE POINT

1 Charcot had a remarkable and admirable ability to see what was new and what was logically linked, and his name is associated with many other medical conditions.

RELATED ARTICLE: PAGE POINTS

1 Although over 200 papers and numerous book chapters have been devoted to Charcot's osteoarthropathy, there is no consensus on what is the most appropriate or correct name.

2 Many authors have allocated different names to Charcot's osteoarthropathy in articles authored or co-authored by them over a period of time.

3 Clinicians managing Charcot's osteoarthropathy need to know the name of the disease, the stage, the site affected, the type and degree of residual deformity after the acute stage has resolved, and the presence of ulceration, infection or instability of a joint.

RELATED ARTICLE: PAGE POINTS

1 Charcot's osteoarthropathy is not just an arthropathy; it can also affect bone alone, so it is properly described as an osteoarthropathy.

2 Although Charcot described many other diseases and syndromes, he did not describe any other bone and joint condition, so there is no possibility of confusion when we refer to Charcot's osteoarthropathy.

Ali Foster is Honorary Consultant Podiatrist at the Diabetic foot Clinic, King's College Hospital, London.

COPYRIGHT 2005 S.B. Communications
COPYRIGHT 2005 Gale Group

Return to Charcot disease
Home Contact Resources Exchange Links ebay